{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:31:19Z","timestamp":1782397879818,"version":"3.54.5"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001547","name":"China Medical Board","doi-asserted-by":"crossref","award":["Grant 19-318, A Demonstration Program on Health Technology Assessment in China"],"award-info":[{"award-number":["Grant 19-318, A Demonstration Program on Health Technology Assessment in China"]}],"id":[{"id":"10.13039\/100001547","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To assess the reporting quality of published economic evaluations of the negotiated oncology drugs listed for China\u2019s 2020 National Reimbursement Drug List (NRDL).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A comprehensive search was conducted to identify economic evaluation studies of negotiated oncology drugs listed in China\u2019s 2020 NRDL using the PubMed\/MEDLINE, Embase, Web of Science, CNKI, SinoMed, and WanFang Database up to March 31, 2021. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist scored the reporting quality between 0 and 100. A linear regression analysis was employed to examine the influence of various characteristics on the reporting quality scores.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eighty papers were included in the study, with the majority published during the past decade. Furthermore, more than half of the articles (57.5%, or 46 out of 80) were written in English. The average CHEERS score was 74.63\u2009\u00b1\u200912.75 and ranged from 43.48 to 93.75. The most inadequately reported items included choice of model, characterization of heterogeneity, and discussion, as well as currency, price date and conversion. Higher scores were associated with articles published from 2019 to 2021 and English publications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The economic evaluation studies of negotiated oncology drugs listed in 2020 NRDL had moderate reporting quality. The Chinese economic evaluation publications could improve the reporting quality if the CHEERS checklist is consistently implemented. Also, the Chinese journals maybe explore introducing a reporting standard for economic evaluations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-022-08858-7","type":"journal-article","created":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T11:02:49Z","timestamp":1670065369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Were economic evaluations well reported for the newly listed oncology drugs in China\u2019s national reimbursement drug list"],"prefix":"10.1186","volume":"22","author":[{"given":"Liu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,3]]},"reference":[{"issue":"3","key":"8858_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/14737167.2019.1605292","volume":"22","author":"Y Xiong","year":"2022","unstructured":"Xiong Y, Cui Y, Zhang X. Pharmaceutical expenditure and total health-care expenditure in OECD countries and China: bidirectional Granger causality on the basis of health level. Expert Rev Pharmacoecon Outcomes Res. 2022;22(3):502\u201312.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"8858_CR2","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1186\/s12913-020-05849-4","volume":"20","author":"X Zhang","year":"2020","unstructured":"Zhang X, Lai H, Zhang L, He J, Fu B, Jin C. The impacts and unintended consequences of the nationwide pricing reform for drugs and medical services in the urban public hospitals in China. BMC Health Serv Res. 2020;20(1):1058.","journal-title":"BMC Health Serv Res"},{"key":"8858_CR3","volume-title":"China\u2019s health statistics yearbook","author":"China NHCotPsRo","year":"2021","unstructured":"China NHCotPsRo. China\u2019s health statistics yearbook. Beijing: China Peking Union Medical University Press; 2021."},{"issue":"1 Suppl","key":"8858_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jval.2011.11.026","volume":"15","author":"EY Yim","year":"2012","unstructured":"Yim EY, Lim SH, Oh MJ, Park HK, Gong JR, Park SE, Yi SY. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea. Value Health. 2012;15(1 Suppl):104\u201310.","journal-title":"Value Health"},{"issue":"1","key":"8858_CR5","doi-asserted-by":"publisher","first-page":"e002256","DOI":"10.1136\/bmjgh-2019-002256","volume":"5","author":"L Si","year":"2020","unstructured":"Si L, Xu L, Chen M, Jan S. Using strategic price negotiations to contain costs and expand access to medicines in China. BMJ Glob Health. 2020;5(1):e002256.","journal-title":"BMJ Glob Health"},{"key":"8858_CR6","unstructured":"Notice of General Office of the National Health and Family Planning Commission on the results of national drug price negotiations. http:\/\/www.gov.cn\/xinwen\/2016-05\/20\/content_5075027.htm."},{"issue":"10204","key":"8858_CR7","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","volume":"394","author":"M Zhou","year":"2019","unstructured":"Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, Li X, Wang L, Wang L, Liu Y, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2019;394(10204):1145\u201358.","journal-title":"Lancet"},{"key":"8858_CR8","unstructured":"Global Burden of Disease Study 2019 (GBD 2019) Data Resources. https:\/\/ghdx.healthdata.org\/gbd-2019."},{"issue":"4","key":"8858_CR9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.20892\/j.issn.2095-3941.2020.0387","volume":"17","author":"D Sun","year":"2020","unstructured":"Sun D, Li H, Cao M, He S, Lei L, Peng J, Chen W. Cancer burden in China: trends, risk factors and prevention. Cancer Biol Med. 2020;17(4):879\u201395.","journal-title":"Cancer Biol Med"},{"issue":"3","key":"8858_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/tcrm.2006.2.3.317","volume":"2","author":"CA Uyl-de Groot","year":"2006","unstructured":"Uyl-de Groot CA, McDonnell J, Ten Velde G, Radice D, Groen HJ. Cost-effectiveness of hypothetical new cancer drugs in patients with advanced small-cell lung cancer: results of a markov chain model. Ther Clin Risk Manag. 2006;2(3):317\u201323.","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"8858_CR11","doi-asserted-by":"publisher","first-page":"e212026","DOI":"10.1001\/jamaoncol.2021.2026","volume":"7","author":"KN Vokinger","year":"2021","unstructured":"Vokinger KN, Hwang TJ, Daniore P, Lee CC, Tibau A, Grischott T, Rosemann TJ, Kesselheim AS. Analysis of Launch and Postapproval Cancer Drug pricing, Clinical Benefit, and Policy Implications in the US and Europe. JAMA Oncol. 2021;7(9):e212026.","journal-title":"JAMA Oncol"},{"key":"8858_CR12","unstructured":"Notice of the ministry of human resources and social security on the inclusion of 36 drugs in the category B of the national basic medical insurance, work injury insurance and maternity insurance drug list. http:\/\/www.gov.cn\/xinwen\/2017-07\/19\/content_5211741.htm#2."},{"key":"8858_CR13","unstructured":"Notice of the National Healthcare Security Administration on the Inclusion of 17 Oncology Drugs in the Category B of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List. http:\/\/www.gov.cn\/xinwen\/2018-10\/10\/content_5328891.htm."},{"key":"8858_CR14","unstructured":"Notice of the National Healthcare Security Administration, the Ministry of Human Resources and Social Security on the Inclusion of the 2019 Negotiated Drugs in the Category B of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List. http:\/\/www.nhsa.gov.cn\/art\/2019\/11\/28\/art_38_2056.html."},{"key":"8858_CR15","unstructured":"Notice of the National Healthcare Security Administration, the Ministry of Human Resources and Social Security on the Inclusion of the 2020 Negotiated Drugs in the Category B of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List. http:\/\/www.nhsa.gov.cn\/art\/2020\/12\/28\/art_38_4219.html."},{"issue":"1","key":"8858_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","volume":"23","author":"M Hasegawa","year":"2020","unstructured":"Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal implementation of cost-effectiveness evaluations in Japan: a Unique Health Technology Assessment System. Value Health. 2020;23(1):43\u201351.","journal-title":"Value Health"},{"key":"8858_CR17","unstructured":"\u201cThirteenth five-year Plan\u201d to deepen the reform of the medical and health system.\u00a0http:\/\/www.nhsa.gov.cn\/art\/2016\/12\/27\/art_44_1110.html."},{"issue":"9","key":"8858_CR18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40273-013-0074-1","volume":"31","author":"M Franken","year":"2013","unstructured":"Franken M, Nilsson F, Sandmann F, de Boer A, Koopmanschap M. Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in dutch and swedish reimbursement decision making. PharmacoEconomics. 2013;31(9):781\u201397.","journal-title":"PharmacoEconomics"},{"issue":"6","key":"8858_CR19","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.jval.2015.06.007","volume":"18","author":"SM Sullivan","year":"2015","unstructured":"Sullivan SM, Wells G, Coyle D. What Guidance are economists given on how to present economic evaluations for policymakers? A systematic review. Value Health. 2015;18(6):915\u201324.","journal-title":"Value Health"},{"issue":"41","key":"8858_CR20","doi-asserted-by":"publisher","first-page":"e5114","DOI":"10.1097\/MD.0000000000005114","volume":"95","author":"H Ma","year":"2016","unstructured":"Ma H, Jian W, Xu T, He Y, Rizzo JA, Fang H. Quality of pharmacoeconomic research in China: a systematic review. Med (Baltim). 2016;95(41):e5114.","journal-title":"Med (Baltim)"},{"issue":"5","key":"8858_CR21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1080\/14737167.2020.1800455","volume":"21","author":"L Si","year":"2021","unstructured":"Si L, Yin M, Wang J, Yang S, Zhang J, Wei L. Evaluation of quality of pharmacoeconomic studies involved in traditional chinese medicine in China. Expert Rev Pharmacoecon Outcomes Res. 2021;21(5):1049\u201360.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"8858_CR22","unstructured":"National Healthcare Security. Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS).\u00a0 http:\/\/www.nhsa.gov.cn\/art\/2020\/12\/28\/art_37_4220.html."},{"issue":"2","key":"8858_CR23","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated Health Economic evaluation reporting Standards (CHEERS) statement. Value Health. 2013;16(2):e1\u20135.","journal-title":"Value Health"},{"issue":"2","key":"8858_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated Health Economic evaluation reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic evaluation publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231\u201350.","journal-title":"Value Health"},{"issue":"1","key":"8858_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40258-021-00674-0","volume":"20","author":"J Cheng","year":"2022","unstructured":"Cheng J, Zhang Y, Zhong A, Tian M, Zou G, Chen X, et al. Quality of health economic evaluations in Mainland China: a comparison of peer-reviewed articles in Chinese and in English. Appl Health Econ Health Policy. 2022;20(1):35\u201354.","journal-title":"Appl Health Econ Health Policy"},{"key":"8858_CR26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jclinepi.2017.12.006","volume":"98","author":"AF Schmidt","year":"2018","unstructured":"Schmidt AF, Finan C. Linear regression and the normality assumption. J Clin Epidemiol. 2018;98:146\u201351.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"8858_CR27","first-page":"7","volume":"11","author":"S Bian","year":"2016","unstructured":"Bian S, Liu Y, Liu GG. Cost-effectivness analysis of second-line chemotherapy therapies for metastatic colorectal cancer. China J Pharm Econ. 2016;11(2):7\u201310.","journal-title":"China J Pharm Econ"},{"issue":"24","key":"8858_CR28","first-page":"2268","volume":"23","author":"W Linghuan","year":"2012","unstructured":"Linghuan W, Jiahong H. Cost-effectiveness analysis of 2 dosage forms of Paclitaxel combined with carboplatin for first-line treatment of Advanced Ovarian Cancer. China Pharm. 2012;23(24):2268\u201370.","journal-title":"China Pharm"},{"issue":"6","key":"8858_CR29","first-page":"1108","volume":"43","author":"F Xiaofeng","year":"2020","unstructured":"Xiaofeng F, Huiyu Y, Shan X. Cost-effectiveness analysis of paclitaxel combined with carboplatin in patients with recurrent ovarian cancer. Drug Evaluation Research. 2020;43(6):1108\u201311.","journal-title":"Drug Evaluation Research"},{"issue":"1","key":"8858_CR30","doi-asserted-by":"publisher","first-page":"107327482090227","DOI":"10.1177\/1073274820902271","volume":"27","author":"J Han","year":"2020","unstructured":"Han J, Xiao D, Tan C, Zeng X, Hu H, Zeng S, Jiang Q, She L, Yao L, Li L, et al. Cost-effectiveness analysis of First-Line FOLFIRI Combined with Cetuximab or Bevacizumab in patients with RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. Cancer Control. 2020;27(1):1073274820902271.","journal-title":"Cancer Control"},{"key":"8858_CR31","doi-asserted-by":"publisher","first-page":"10419","DOI":"10.2147\/CMAR.S219318","volume":"11","author":"L Bai","year":"2019","unstructured":"Bai L, Zhang P, Zhou K, Liao W, Li Q. Cost-effectiveness analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with RAS Wild-Type Metastatic Colorectal Cancer. Cancer Manag Res. 2019;11:10419\u201326.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"8858_CR32","doi-asserted-by":"publisher","first-page":"e030738","DOI":"10.1136\/bmjopen-2019-030738","volume":"10","author":"H Wang","year":"2020","unstructured":"Wang H, Huang L, Gao P, Zhu Z, Ye W, Ding H, Fang L. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial. BMJ Open. 2020;10(2):e030738.","journal-title":"BMJ Open"},{"issue":"11","key":"8858_CR33","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1080\/15384047.2015.1095398","volume":"16","author":"F Wen","year":"2015","unstructured":"Wen F, Yang Y, Zhang P, Zhang J, Zhou J, Tang R, Chen H, Zheng H, Fu P, Li Q. Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 study. Cancer Biol Ther. 2015;16(11):1577\u201384.","journal-title":"Cancer Biol Ther"},{"issue":"27","key":"8858_CR34","doi-asserted-by":"publisher","first-page":"e3762","DOI":"10.1097\/MD.0000000000003762","volume":"95","author":"J Zhou","year":"2016","unstructured":"Zhou J, Zhao R, Wen F, Zhang P, Tang R, Chen H, Zhang J, Li Q. Economic evaluation study (CHEER-compliant): cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial. Med (Baltim). 2016;95(27):e3762.","journal-title":"Med (Baltim)"},{"issue":"24","key":"8858_CR35","first-page":"2969","volume":"27","author":"L Mei","year":"2018","unstructured":"Mei L, Wei Z, Guolong Z, Chunxiang Z. Cost-utility analysis of KRAS testing and cetuximab as first-line therapy for metastatic colorectal cancer. Chin J NewDrugs. 2018;27(24):2969\u201376.","journal-title":"Chin J NewDrugs"},{"issue":"41","key":"8858_CR36","doi-asserted-by":"publisher","first-page":"71164","DOI":"10.18632\/oncotarget.17029","volume":"8","author":"B Wu","year":"2017","unstructured":"Wu B, Yao Y, Zhang K, Ma X. RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources. Oncotarget. 2017;8(41):71164\u201372.","journal-title":"Oncotarget"},{"issue":"7","key":"8858_CR37","first-page":"421","volume":"24","author":"T Jing","year":"2015","unstructured":"Jing T, Zhengyue L, Pingping Y, Zhuo W, Shen G. Economic analysis of Cetuximab in Therapy of Metastatic Colorectal Cancer. Chin J Pharmacoepidemiology. 2015;24(7):421\u20134.","journal-title":"Chin J Pharmacoepidemiology"},{"issue":"6","key":"8858_CR38","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1002\/cam4.3733","volume":"10","author":"WQ Li","year":"2021","unstructured":"Li WQ, Li LY, Chai J, Cui JW. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients. Cancer Med. 2021;10(6):1964\u201374.","journal-title":"Cancer Med"},{"issue":"11","key":"8858_CR39","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.clinthera.2020.08.018","volume":"42","author":"M Rui","year":"2020","unstructured":"Rui M, Li H. Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in third-line treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China. Clin Ther. 2020;42(11):2159\u201370.e2156.","journal-title":"Clin Ther"},{"issue":"5","key":"8858_CR40","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/liv.14795","volume":"41","author":"F Wen","year":"2021","unstructured":"Wen F, Zheng H, Zhang P, Liao W, Zhou K, Li Q. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis in China and the United states. Liver Int. 2021;41(5):1097\u2013104.","journal-title":"Liver Int"},{"key":"8858_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2018.05.001","volume":"18","author":"X Li","year":"2019","unstructured":"Li X, Li W, Hou L. A trial-based cost-effectiveness analysis of Bevacizumab and Chemotherapy Versus Chemotherapy alone for Advanced Nonsquamous Non-Small-Cell Lung Cancer in China. Value Health Reg Issues. 2019;18:1\u20137.","journal-title":"Value Health Reg Issues"},{"issue":"3","key":"8858_CR42","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s12094-017-1715-1","volume":"20","author":"H Zheng","year":"2018","unstructured":"Zheng H, Xie L, Zhan M, Wen F, Xu T, Li Q. Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer. Clin Transl Oncol. 2018;20(3):286\u201393.","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"8858_CR43","first-page":"925","volume":"12","author":"G Xiaohong","year":"2014","unstructured":"Xiaohong G, Yuanxin G, Haoyang D. Cost-effectiveness of fi rst-line chemotherapy with bevacizumab for patients with advanced non-small-cell lung cancer. Cent South Pharm. 2014;12(9):925\u20138.","journal-title":"Cent South Pharm"},{"issue":"1","key":"8858_CR44","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12094-019-02114-x","volume":"22","author":"PF Zhang","year":"2020","unstructured":"Zhang PF, Wen F, Zhou J, Huang JX, Zhou KX, Wu QJ, Wang XY, Zhang MX, Liao WT, Li Q. Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from chinese societal perspective. Clin Transl Oncol. 2020;22(1):103\u201310.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"8858_CR45","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13014-020-01674-5","volume":"15","author":"Z Fei","year":"2020","unstructured":"Fei Z, Xu T, Li M, Chen T, Li L, Qiu X, Chen C. Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma. Radiat Oncol. 2020;15(1):230.","journal-title":"Radiat Oncol"},{"issue":"Suppl 3","key":"8858_CR46","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1524-4733.2009.00634.x","volume":"12","author":"W Chen","year":"2009","unstructured":"Chen W, Jiang Z, Shao Z, Sun Q, Shen K. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value Health. 2009;12(Suppl 3):82\u20134.","journal-title":"Value Health"},{"issue":"2","key":"8858_CR47","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.clinthera.2012.01.012","volume":"34","author":"B Wu","year":"2012","unstructured":"Wu B, Ye M, Chen H, Shen JF. Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the chinese context. Clin Ther. 2012;34(2):468\u201379.","journal-title":"Clin Ther"},{"issue":"8","key":"8858_CR48","first-page":"696","volume":"52","author":"C Wei","year":"2017","unstructured":"Wei C, Sujian X, He L, Yongqing L, Zhan Z. A cost-effectiveness analysis of adjuvant trastuzumab regimens in HER2-Positive early breast cancer. Chin Pharm J. 2017;52(8):696\u2013701.","journal-title":"Chin Pharm J"},{"issue":"11","key":"8858_CR49","first-page":"72","volume":"36","author":"G Wenbo","year":"2017","unstructured":"Wenbo G, Juyang X, Han Z, yu S, dandan G. Evaluationon Pharmacoeconomicof trastuzumab in the adjuvant treatment for early HER2- positive breast cancer. Chin Health Econ. 2017;36(11):72\u20135.","journal-title":"Chin Health Econ"},{"issue":"5","key":"8858_CR50","first-page":"577","volume":"26","author":"R Peipei","year":"2015","unstructured":"Peipei R, Jinchun S, Yue W. Cost-effectiveness analysis of trastuzumab combined with chemotherapy for Her-2 positive advanced gastric cancer. China Pharm. 2015;26(5):577\u20139.","journal-title":"China Pharm"},{"issue":"8","key":"8858_CR51","first-page":"560","volume":"27","author":"D Xiaoying","year":"2017","unstructured":"Xiaoying D, Xiaohong Z, Jie C, Guohao L. Pharmacoeconomic evaluation of Trastuzumabin adjuvant treatment for breast cancer. Pharm Today. 2017;27(8):560\u20133.","journal-title":"Pharm Today"},{"issue":"4","key":"8858_CR52","first-page":"35","volume":"25","author":"H Jingjing","year":"2016","unstructured":"Jingjing H, Xiaolei Y, Yue Z. Cost-efficacy analysis and influence on compliance of trastuzumab for treating HER-2 positive breast cancer. Drug \u00ef\u00bc\u00b2esearch. 2016;25(4):35\u20137.","journal-title":"Drug \u00ef\u00bc\u00b2esearch"},{"issue":"1","key":"8858_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12962-021-00264-w","volume":"19","author":"Q Xu","year":"2021","unstructured":"Xu Q, Yuanyuan L, Jiejing Z, Jian L, Qingyu L, Lingya C, Ying L, Changchen S, Yangling L, Wei Y. Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china. Cost Eff Resour Alloc. 2021;19(1):11.","journal-title":"Cost Eff Resour Alloc"},{"issue":"8","key":"8858_CR54","first-page":"985","volume":"36","author":"X Qiaoping","year":"2019","unstructured":"Qiaoping X, Jiejin Z, Jian L, Lingya C, Ying L, Changcheng S, Yangling L, Biqin T, Wei Y. Cost-effectiveness analysis of two neoadjuvant chemotherapy in HER2-positive breast cancer patient. Chin J Mod Appl Pharm. 2019;36(8):985\u201392.","journal-title":"Chin J Mod Appl Pharm"},{"issue":"2","key":"8858_CR55","first-page":"62","volume":"40","author":"S Fenghao","year":"2021","unstructured":"Fenghao S, Rui M, Zijing W, Mingjun R, Ye S, Aixia M. Cost-effectiveness analysis of applying camrelizumab as second-Line therapy for the treatment of advanced hepa- tocellular carcinoma. Chin Health Econ. 2021;40(2):62\u20135.","journal-title":"Chin Health Econ"},{"issue":"12","key":"8858_CR56","first-page":"1689","volume":"39","author":"W Hao","year":"2020","unstructured":"Hao W, Chenxin Z, Li L, Weihong G. Cost-effectiveness analysis of osimertinib and gefitinib \/erlotinib as the first-line therapy for EGF\u00ef\u00bc\u00b2-mutated advanced non-small-cell Lung cancer. Herald Med. 2020;39(12):1689\u201396.","journal-title":"Herald Med"},{"issue":"2","key":"8858_CR57","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.clinthera.2018.12.007","volume":"41","author":"H Cai","year":"2019","unstructured":"Cai H, Zhang L, Li N, Chen S, Zheng B, Yang J, Weng L, Liu MB. Cost-effectiveness of osimertinib as first-line treatment and sequential therapy for EGFR mutation-positive non-small cell lung cancer in China. Clin Ther. 2019;41(2):280\u201390.","journal-title":"Clin Ther"},{"issue":"3","key":"8858_CR58","doi-asserted-by":"publisher","first-page":"e55917","DOI":"10.1371\/journal.pone.0055917","volume":"8","author":"S Wang","year":"2013","unstructured":"Wang S, Peng L, Li J, Zeng X, Ouyang L, Tan C, Lu Q. A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for eastern asian nonsquamous non-small-cell lung cancer. PLoS ONE. 2013;8(3):e55917.","journal-title":"PLoS ONE"},{"key":"8858_CR59","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.lungcan.2018.11.029","volume":"127","author":"X Gu","year":"2019","unstructured":"Gu X, Zhang Q, Chu YB, Zhao YY, Zhang YJ, Kuo D, Su B, Wu B. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lung Cancer. 2019;127:84\u20139.","journal-title":"Lung Cancer"},{"issue":"5","key":"8858_CR60","first-page":"305","volume":"30","author":"K Qian","year":"2013","unstructured":"Qian K, Zheng Y. Pharmacoeconomic evaluation of EGF\u00ef\u00bc\u00b2-TKIs in the treatment of advanced non-small cell lung cancer. Chin J Drug Eval. 2013;30(5):305\u20138.","journal-title":"Chin J Drug Eval"},{"issue":"6","key":"8858_CR61","first-page":"377","volume":"30","author":"K Qian","year":"2013","unstructured":"Qian K, Danni X, Zheng Y. Cost-effectiveness analysis of EGF\u00ef\u00bc\u00b2-TKIs in the treatment of advanced non-small cell lung cancer. Chin J Drug Eval. 2013;30(6):377\u201380.","journal-title":"Chin J Drug Eval"},{"issue":"4","key":"8858_CR62","doi-asserted-by":"publisher","first-page":"e020128","DOI":"10.1136\/bmjopen-2017-020128","volume":"8","author":"F Wen","year":"2018","unstructured":"Wen F, Zheng H, Zhang P, Hutton D, Li Q. OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of asian patients with non-squamous non-small-cell lung cancer. BMJ Open. 2018;8(4):e020128.","journal-title":"BMJ Open"},{"issue":"2","key":"8858_CR63","first-page":"138","volume":"35","author":"O Liying","year":"2016","unstructured":"Liying O. Cost - effectiveness evaluation of two first - line chemotherapy regimens in advanced non - small cell lung cancer patients with epidermal growth factor receptor mutation. Chin J New Drugs Clin Remedies. 2016;35(2):138\u201344.","journal-title":"Chin J New Drugs Clin Remedies"},{"issue":"4","key":"8858_CR64","first-page":"203","volume":"16","author":"Y MA","year":"2013","unstructured":"MA Y, Huang Y, Zhao H, Liu J, Chen L, Wu H. The cost-effectiveness analysis of gefitinib or Erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients. Chin J Lung Cancer. 2013;16(4):203\u201310.","journal-title":"Chin J Lung Cancer"},{"issue":"2","key":"8858_CR65","first-page":"143","volume":"29","author":"B Liangyu","year":"2016","unstructured":"Liangyu B, Min L, Beibei C, Huifang L, Lili H, Hongzhi Z, Weijie Z, Qingxia F, Liuxing W, Xiaobing C, et al. Clinical effect and pharmacoeconomics analysis of EGFR-TKI in the treatment of advanced non-small cell lung cancer. J Basic Clin Oncol. 2016;29(2):143\u20136.","journal-title":"J Basic Clin Oncol"},{"issue":"3","key":"8858_CR66","first-page":"167","volume":"27","author":"Z Yun","year":"2018","unstructured":"Yun Z, Meiling Z. Analysis of the direct medical cost of targeted therapy for non-small cell lung cancer. Chin J Clin Pharm. 2018;27(3):167\u201371.","journal-title":"Chin J Clin Pharm"},{"issue":"4","key":"8858_CR67","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3892\/etm.2021.9774","volume":"21","author":"W LI","year":"2021","unstructured":"LI W, Qian L, Li W, Chen X, He H, Tian H, Zhao Y, Wang X, Cui J. Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer. Exp Ther Med. 2021;21(4):343.","journal-title":"Exp Ther Med"},{"issue":"2","key":"8858_CR68","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jtho.2017.10.012","volume":"13","author":"B Wu","year":"2018","unstructured":"Wu B, Gu X, Zhang Q. Cost-effectiveness of osimertinib for EGFR mutation-positive non-small cell lung cancer after progression following first-line EGFR TKI therapy. J Thorac Oncol. 2018;13(2):184\u201393.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"8858_CR69","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1634\/theoncologist.2018-0150","volume":"24","author":"B Wu","year":"2019","unstructured":"Wu B, Gu X, Zhang Q, Xie F. Cost-effectiveness of osimertinib in treating newly diagnosed, advanced EGFR-mutation-positive non small cell lung cancer. Oncologist. 2019;24(3):349\u201357.","journal-title":"Oncologist"},{"issue":"3","key":"8858_CR70","first-page":"205","volume":"40","author":"Y Yihua","year":"2021","unstructured":"Yihua Y, Yue Y, Yuanqiu P. Cost-effectiveness analysis of osimertinib as first-line therapy in locally advanced or metastatic NSCLC with an EGFR mutation. Chin J New Drugs Clin Remedies. 2021;40(3):205\u20139.","journal-title":"Chin J New Drugs Clin Remedies"},{"issue":"11","key":"8858_CR71","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.clinthera.2019.09.008","volume":"41","author":"HJ Guan","year":"2019","unstructured":"Guan HJ, Liu GD, Xie F, Sheng YN, Shi LW. Cost-effectiveness of osimertinib as a second-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer in China. Clin Ther. 2019;41(11):2308\u201320.","journal-title":"Clin Ther"},{"key":"8858_CR72","unstructured":"Haijing G, Guoen L, Yanan S, Yanan W, Hongchao L. Cost-effectiveness of osimertinib in non-small cell lung cancer (NSCLC) patients. China Health Insur.\u00a02018(5):46\u201354."},{"issue":"2","key":"8858_CR73","first-page":"172","volume":"39","author":"Z Mei","year":"2020","unstructured":"Mei Z, Bin W, Fengbo W, Ting X. Cost-effectiveness analysis of anlotinib for advanced non-small cell lung cancer. Herald of Medicine. 2020;39(2):172\u20135.","journal-title":"Herald Med"},{"issue":"6","key":"8858_CR74","first-page":"380","volume":"39","author":"Z Jin","year":"2020","unstructured":"Jin Z, Lihong R, Dong L, Ziyun L, Xiaoyu Z, Yiping W, Beibei Y, Fengli J. Cost-effectiveness analysis of anlotinib in treating advanced non-small cell lung cancer. Chin J New Drugs Clin Remedies. 2020;39(6):380\u20134.","journal-title":"Chin J New Drugs Clin Remedies"},{"issue":"5","key":"8858_CR75","first-page":"19","volume":"37","author":"D Haiying","year":"2020","unstructured":"Haiying D, Sisi K, Jiao S, Gaoqi X, Chaoneng H, Ping H. Cost-effectiveness analysis of anlotinib hydrochloride for treatment of advanced non-small cell lung cancer. Health Econ Res. 2020;37(5):19\u201322.","journal-title":"Health Econ Res"},{"issue":"2","key":"8858_CR76","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40261-019-00880-8","volume":"40","author":"H Li","year":"2020","unstructured":"Li H, Lai L, Wu B. Cost effectiveness of ceritinib and alectinib versus crizotinib in first-line anaplastic lymphoma kinase positive advanced non-small-cell lung cancer. Clin Drug Investig. 2020;40(2):183\u20139.","journal-title":"Clin Drug Investig"},{"key":"8858_CR77","doi-asserted-by":"publisher","first-page":"9195","DOI":"10.2147\/CMAR.S223441","volume":"11","author":"M Liu","year":"2019","unstructured":"Liu M, Zhang L, Huang Q, Li N, Zheng B, Cai H. Cost-effectiveness analysis of ceritinib and alectinib versus crizotinib in the treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. Cancer Manag Res. 2019;11:9195\u2013202.","journal-title":"Cancer Manag Res"},{"key":"8858_CR78","unstructured":"Li Z, Caicun Z, Jun Z, Jie H, Xiaorong D, Jian M. Cost-effectiveness study of alectinib compared with crizotinib in first-line treatment for ALK positive advanced NSCLC in China.Chin Health Insur\u00a02019(12):56\u201362."},{"issue":"2","key":"8858_CR79","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2217\/cer-2019-0075","volume":"9","author":"M Huang","year":"2020","unstructured":"Huang M, Tian Y, He M, Liu J, Ren L, Gong Y, Peng F, Wang Y, Ding Z, Wang J, et al. Crizotinib versus chemotherapy: a real-world cost-effectiveness study in China. J Comp Eff Res. 2020;9(2):93\u2013102.","journal-title":"J Comp Eff Res"},{"issue":"4","key":"8858_CR80","first-page":"234","volume":"29","author":"L Weicheng","year":"2019","unstructured":"Weicheng L, Baoping D, Xiaoquan L, Tao L. Cost-effectiveness analysis of Crizotinib using in Advanced NSCLC. Pharm Today. 2019;29(4):234\u201347.","journal-title":"Pharm Today"},{"issue":"6","key":"8858_CR81","first-page":"1119","volume":"23","author":"M Lifeng","year":"2020","unstructured":"Lifeng M, Xianxi G, Yanru H, Ling H, Peipei R, Benhong Z. Cost-effectiveness analysis of crizotinib in first-line treatment of ALK-positive non-small cell lung cancer. China Pharmacist. 2020;23(6):1119\u201323.","journal-title":"China Pharmacist"},{"issue":"8","key":"8858_CR82","first-page":"86","volume":"31","author":"Z Longfen","year":"2019","unstructured":"Longfen Z, Qi-shu H, Lingling Q, Xiuqin L, Hongfu C. Cost-effectiveness analysis of ceritinib versus alectinib for first-line treatment of ALK-positive advanced non-small cell lung cancer. Strait Pharm J. 2019;31(8):86\u20139.","journal-title":"Strait Pharm J"},{"issue":"11","key":"8858_CR83","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1007\/s12325-019-01103-4","volume":"36","author":"Y Peng","year":"2019","unstructured":"Peng Y, Ma F, Tan C, Wan X, Yi L, Peng L, Zeng X. Model-based economic evaluation of ceritinib and platinum-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Adv Therapy. 2019;36(11):3047\u201358.","journal-title":"Adv Therapy"},{"issue":"5","key":"8858_CR84","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1499-3872(17)60009-2","volume":"16","author":"RC Zhao","year":"2017","unstructured":"Zhao RC, Zhou J, Wei YG, Liu F, Chen KF, Li Q, Li B. Cost-effectiveness anallysis of transcatheter irterOaV chernoernboOlization with or without sorafenib for the treatment of unresectablie hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2017;16(5):493\u20138.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"12","key":"8858_CR85","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1111\/jgh.13425","volume":"31","author":"P Zhang","year":"2016","unstructured":"Zhang P, Yang Y, Wen F, Wheeler J, Fu P, Li Q. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. J Gastroenterol Hepatol. 2016;31(12):1978\u201385.","journal-title":"J Gastroenterol Hepatol"},{"key":"8858_CR86","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12962-018-0112-0","volume":"16","author":"S Qin","year":"2018","unstructured":"Qin S, Kruger E, Tan SC, Cheng S, Wang N, Liang J. Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China. Cost Eff Resour Alloc. 2018;16:29.","journal-title":"Cost Eff Resour Alloc"},{"issue":"7","key":"8858_CR87","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1097\/MEG.0000000000000373","volume":"27","author":"P Zhang","year":"2015","unstructured":"Zhang P, Yang Y, Wen F, He X, Tang R, Du Z, Zhou J, Zhang J, Li Q. Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2015;27(7):853\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"12","key":"8858_CR88","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.dld.2016.07.007","volume":"48","author":"P Zhang","year":"2016","unstructured":"Zhang P, Wen F, Li Q. FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: a cost-effectiveness analysis. Dig Liver Dis. 2016;48(12):1492\u20137.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"8858_CR89","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12885-018-4308-7","volume":"18","author":"S Chen","year":"2018","unstructured":"Chen S, Peng Z, Wei M, Liu W, Dai Z, Wang H, Mei J, Cheong M, Zhang H, Kuang M. Sorafenib versus transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis. BMC Cancer. 2018;18(1):392.","journal-title":"BMC Cancer"},{"issue":"3","key":"8858_CR90","first-page":"178","volume":"30","author":"Z Xinke","year":"2013","unstructured":"Xinke Z, Jing W, Aixia M. Cost-effectiveness of sequential therapies of sunitinib and sorafenib in metastatic \u00ef\u00bc\u00b2enal cell carcinoma. Chin J Drug Evaluation. 2013;30(3):178\u201383.","journal-title":"Chin J Drug Evaluation"},{"issue":"26","key":"8858_CR91","first-page":"2401","volume":"23","author":"Y Huaiyong","year":"2012","unstructured":"Huaiyong Y, Long Y, Youwei X, Xuan W. Pharmacoeconomic evaluation of sunitinib for the treatment of metastatic renal cell carcinoma. Chin Pharm. 2012;23(26):2401\u20134.","journal-title":"Chin Pharm"},{"issue":"1","key":"8858_CR92","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/13696998.2021.1888743","volume":"24","author":"X Guan","year":"2021","unstructured":"Guan X, Li H, Xiong X, Peng C, Wang N, Ma X, Ma A. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China. J Med Econ. 2021;24(1):339\u201344.","journal-title":"J Med Econ"},{"issue":"2","key":"8858_CR93","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00432-016-2296-z","volume":"143","author":"HD Chen","year":"2017","unstructured":"Chen HD, Zhou J, Wen F, Zhang PF, Zhou KX, Zheng HR, Yang Y, Li Q. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. J Cancer Res Clin Oncol. 2017;143(2):361\u20138.","journal-title":"J Cancer Res Clin Oncol"},{"key":"8858_CR94","doi-asserted-by":"publisher","first-page":"2816737","DOI":"10.1155\/2017\/2816737","volume":"2017","author":"Y Bai","year":"2017","unstructured":"Bai Y, Xu Y, Wu B. Cost-effectiveness and budget impact analysis of apatinib for advanced metastatic gastric cancer from the perspective of health insurance system. Gastroenterol Res Pract. 2017;2017:2816737.","journal-title":"Gastroenterol Res Pract"},{"issue":"5","key":"8858_CR95","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1177\/0300891620916789","volume":"106","author":"P-F Zhang","year":"2020","unstructured":"Zhang P-F, Xie D, Li Q. Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer. Tumori J. 2020;106(5):400\u20135.","journal-title":"Tumori J"},{"issue":"1","key":"8858_CR96","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1186\/s12885-020-07486-w","volume":"20","author":"Z Peng","year":"2020","unstructured":"Peng Z, Hou X, Huang Y, Xie T, Hua X. Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China. Bmc Cancer. 2020;20(1):990.","journal-title":"Bmc Cancer"},{"issue":"29","key":"8858_CR97","doi-asserted-by":"publisher","first-page":"e7445","DOI":"10.1097\/MD.0000000000007445","volume":"96","author":"B Wu","year":"2017","unstructured":"Wu B, Liu M, Li T, Lin H, Zhong H. An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: a CHEERS-compliant article. Med (Baltim). 2017;96(29):e7445.","journal-title":"Med (Baltim)"},{"issue":"1","key":"8858_CR98","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40261-017-0587-z","volume":"38","author":"N Li","year":"2018","unstructured":"Li N, Zheng B, Cai HF, Yang J, Luo XF, Weng LZ, Zhan FM, Liu MB. Cost effectiveness of imatinib, dasatinib, and nilotinib as first-line treatment for chronic-phase chronic myeloid leukemia in China. Clin Drug Investig. 2018;38(1):79\u201386.","journal-title":"Clin Drug Investig"},{"issue":"19","key":"8858_CR99","first-page":"1974","volume":"37","author":"X Wei","year":"2017","unstructured":"Wei X, Nan G, Li M, Zhenzhen D. Cost utility analysis of high dose imatinib, dasatinib and nilotinib in treatment of chronic myeloid leukemia. Chin J Hosp Pharm. 2017;37(19):1974\u20138.","journal-title":"Chin J Hosp Pharm"},{"issue":"6","key":"8858_CR100","first-page":"698","volume":"36","author":"C Lin","year":"2016","unstructured":"Lin C, Min Y, Guohua C. Phamacoeconomics evaluation of nilotinib and dasatinib in second-line treament of chronic mycloid leukemia therapy. Tumor. 2016;36(6):698\u2013704,710.","journal-title":"Tumor"},{"issue":"5","key":"8858_CR101","first-page":"57","volume":"37","author":"G Ling","year":"2018","unstructured":"Ling G, Chengfeng H, Yuehua L, Yansui Y. Cost-utility analysis of nilotinib versus high-dose Imatinib for the second-line treatment of patients with chronic myeloid leukemia. Chin Health Econ. 2018;37(5):57\u201361.","journal-title":"Chin Health Econ"},{"issue":"12","key":"8858_CR102","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1080\/10428194.2019.1620947","volume":"60","author":"HF Cai","year":"2019","unstructured":"Cai HF, Zhang LF, Li N, Zheng B, Liu MB. Cost-effectiveness analysis on binary\/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma. Leuk Lymphoma. 2019;60(12):2951\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"8858_CR103","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.clinthera.2011.09.016","volume":"33","author":"B Wu","year":"2011","unstructured":"Wu B, Chen H, Shen J, Ye M. Cost-effectiveness of adding Rh-Endostatin to first-line chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer in China. Clin Ther. 2011;33(10):1446\u201355.","journal-title":"Clin Ther"},{"key":"8858_CR104","doi-asserted-by":"crossref","unstructured":"Lu S, Yu Y, Fu S, Ren H. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China. Plos One. 2018;13(10):e0205827.","DOI":"10.1371\/journal.pone.0205827"},{"issue":"9","key":"8858_CR105","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2217\/pgs-2016-0017","volume":"17","author":"S Lu","year":"2016","unstructured":"Lu S, Zhang J, Ye M, Wang B, Wu B. Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer. Pharmacogenomics. 2016;17(9):985\u201394.","journal-title":"Pharmacogenomics"},{"issue":"5","key":"8858_CR106","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1007\/s12325-019-00908-7","volume":"36","author":"H Guan","year":"2019","unstructured":"Guan H, Sheng Y, Guo W, Han S, Shi L. Cost-effectiveness of Alectinib for patients with untreated ALK-Positive Non-Small Cell Lung Cancer in China. Adv Ther. 2019;36(5):1114\u201325.","journal-title":"Adv Ther"},{"issue":"2","key":"8858_CR107","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.radonc.2017.08.034","volume":"125","author":"C Monten","year":"2017","unstructured":"Monten C, Veldeman L, Verhaeghe N, Lievens Y. A systematic review of health economic evaluation in adjuvant breast radiotherapy: quality counted by numbers. Radiother Oncol. 2017;125(2):186\u201392.","journal-title":"Radiother Oncol"},{"issue":"2","key":"8858_CR108","doi-asserted-by":"publisher","first-page":"e0246080","DOI":"10.1371\/journal.pone.0246080","volume":"16","author":"C Min","year":"2021","unstructured":"Min C, Xue M, Haotian F, Jialian L, Lingli Z. An overview of the characteristics and quality assessment criteria in systematic review of pharmacoeconomics. PLoS ONE. 2021;16(2):e0246080.","journal-title":"PLoS ONE"},{"issue":"3","key":"8858_CR109","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40273-014-0231-1","volume":"33","author":"M Hiligsmann","year":"2015","unstructured":"Hiligsmann M, Evers SM, Ben Sedrine W, Kanis JA, Ramaekers B, Reginster JY, Silverman S, Wyers CE, Boonen A. A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. PharmacoEconomics. 2015;33(3):205\u201324.","journal-title":"PharmacoEconomics"},{"issue":"4","key":"8858_CR110","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/14737167.2021.1858055","volume":"21","author":"S Karekar","year":"2021","unstructured":"Karekar S, Shetty Y. Assessment of the quality and trend of reporting of health economic evaluation research in India. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):595\u20139.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"8858_CR111","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40273-015-0266-y","volume":"33","author":"J Geng","year":"2015","unstructured":"Geng J, Yu H, Mao Y, Zhang P, Chen Y. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. PharmacoEconomics. 2015;33(6):581\u201397.","journal-title":"PharmacoEconomics"},{"issue":"24","key":"8858_CR112","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1016\/j.vaccine.2017.04.050","volume":"35","author":"CKH Wong","year":"2017","unstructured":"Wong CKH, Liao Q, Guo VYW, Xin Y, Lam CLK. Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: a systematic review. Vaccine. 2017;35(24):3153\u201361.","journal-title":"Vaccine"},{"issue":"11","key":"8858_CR113","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1080\/09638288.2020.1830441","volume":"44","author":"J Flemming","year":"2022","unstructured":"Flemming J, Chojecki D, Tjosvold L, Paulden M, Armijo-Olivo S. Quality of reporting of economic evaluations in rehabilitation research: a systematic review. Disabil Rehabil. 2022;44(11):2233\u201340.","journal-title":"Disabil Rehabil"},{"issue":"7430","key":"8858_CR114","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1136\/bmj.328.7430.22","volume":"328","author":"HP Soares","year":"2004","unstructured":"Soares HP, Daniels S, Kumar A, Clarke M, Scott C, Swann S, Djulbegovic B. Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the radiation therapy oncology group. BMJ. 2004;328(7430):22\u20134.","journal-title":"BMJ"},{"key":"8858_CR115","doi-asserted-by":"publisher","first-page":"j2490","DOI":"10.1136\/bmj.j2490","volume":"357","author":"A Dechartres","year":"2017","unstructured":"Dechartres A, Trinquart L, Atal I, Moher D, Dickersin K, Boutron I, Perrodeau E, Altman DG, Ravaud P. Evolution of poor reporting and inadequate methods over time in 20 920 randomised controlled trials included in Cochrane reviews: research on research study. BMJ. 2017;357:j2490.","journal-title":"BMJ"},{"issue":"2","key":"8858_CR116","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/jcpt.12384","volume":"41","author":"PM Aguiar","year":"2016","unstructured":"Aguiar PM, Lima TM, Storpirtis S. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality? J Clin Pharm Ther. 2016;41(2):189\u201397.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"8858_CR117","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1524-4733.2009.00663.x","volume":"13","author":"JW Hay","year":"2010","unstructured":"Hay JW, Smeeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC, Mullins CD, Mycka JM, Seal B, Shi L. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR drug cost Task Force report\u2013part I. Value Health. 2010;13(1):3\u20137.","journal-title":"Value Health"},{"issue":"2","key":"8858_CR118","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/0272989X19900179","volume":"40","author":"H O\u2019Donnell","year":"2020","unstructured":"O\u2019Donnell H, McCullagh L, Barry M, Walsh C. The Interaction between price negotiations and heterogeneity: implications for economic evaluations. Med Decis Making. 2020;40(2):144\u201355.","journal-title":"Med Decis Making"},{"issue":"7","key":"8858_CR119","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jamasurg.2021.0540","volume":"156","author":"OM Fayanju","year":"2021","unstructured":"Fayanju OM, Haukoos JS, Tseng JF. CHEERS reporting guidelines for economic evaluations. JAMA Surg. 2021;156(7):677\u20138.","journal-title":"JAMA Surg"},{"issue":"1","key":"8858_CR120","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139.","journal-title":"Value Health"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08858-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-022-08858-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08858-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T03:04:54Z","timestamp":1670123094000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-022-08858-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,3]]},"references-count":120,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8858"],"URL":"https:\/\/doi.org\/10.1186\/s12913-022-08858-7","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,3]]},"assertion":[{"value":"21 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1475"}}